New York, January 27, 2014 -- Moody's Investors Service assigned a Ba1 rating to the senior notes of Forest Laboratories, Inc. ("Forest"). The rating outlook remains stable. Proceeds are expected to be used together with cash on hand to fund the acquisition of Aptalis Pharma Inc.
Vollständigen Artikel bei Moodys lesen